Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

If you'd like to learn more or get involved, the Dallas Walk to End Alzheimer's starts Saturday morning at 8:30 at Dallas ...

We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024, in conjunction with their partner Biogen's ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...